Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: | Completed |
---|---|
Conditions: | Renal Impairment / Chronic Kidney Disease, Anemia |
Therapuetic Areas: | Hematology, Nephrology / Urology |
Healthy: | No |
Age Range: | Any |
Updated: | 2/4/2013 |
Start Date: | July 2011 |
End Date: | December 2012 |
Contact: | Marietta Franco |
Email: | MFranco@Fibrogen.com |
Phone: | 415-978-1672 |
The purpose of this study is to evaluate efficacy and safety of FG-4592 in the correction of
anemia in patients with end-stage renal disease who recently started dialysis.
Inclusion Criteria:
1. Age 18 to 80 years
2. Receiving hemodialysis or peritoneal dialysis for end- stage renal disease (ESRD) for
2 weeks to 4 months.
3. Hemoglobin < 10 g/dL
4. Body weight 40 to 140 kg
Exclusion Criteria:
1. Previously received erythropoiesis-stimulating agents
2. Received IV iron within 4 weeks prior to randomization
3. Received red blood cell transfusion within 8 weeks prior to randomization
4. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B
surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab)
5. History of chronic liver disease
6. Clinically significant infection
7. New York Heart Association Class III or IV congestive heart failure
8. History of cancer within the past 4 years
9. Chronic inflammatory disease even if it is in remission
10. History of other blood disorders
11. Active hemolysis or diagnosis of hemolytic syndrome
12. Known bone marrow fibrosis
13. Uncontrolled or symptomatic secondary hyperparathyroidism
14. History of alcohol or drug abuse
15. History of allergy or sensitivity to oral or intravenous iron
16. Heart attack, deep vein thrombosis, or pulmonary embolism in the past 3 months
17. Seizure disorder or receiving anti-epilepsy medication
18. Pregnant or breast-feeding females
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials